Atrophic gastritis, intestinal epithelial hyperplasia
Conditions
Interventions
experimental group:Experimental group: vinblastine
Control group:Control group: teprenone
Sponsors
The Seventh Affiliated Hospital Sun Yat-sen University
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1.Age between 18 and 65 years old (inclusive), gender is not limited; 2.The initial diagnosis of gastroscopy and pathology in our hospital met the diagnostic criteria for precancerous diseases of the stomach; 3.Voluntarily participate in this clinical trial, give informed consent and sign the informed consent form.
Exclusion criteria
Exclusion criteria: 1.Autoimmune gastritis (type A chronic atrophic gastritis); 2.People with combined gastric and duodenal ulcers, upper gastrointestinal bleeding or those who need to take other related medications for stomach disorders; 3.Gastric mucosa with high-grade intraepithelial neoplasia, mucosal pathology diagnosis suspecting malignancy; 4.Those with a combination of serious organic diseases, such as serious primary diseases of the heart, brain, liver, kidneys, lungs and haematological system; 5.Persons with a history of allergy to known drugs or ingredients in the study; 6.History of previous gastric surgery (including post-ESD, EMR) or with malignancy; 7.Comorbid severe psychiatric disorders were unable to cooperate with the study; 8.Women who are pregnant or breastfeeding; 9.Patients who are participating in a clinical trial of another drug or who have stopped their last drug study for less than 1 month; 10.Those who cannot co-operate with follow-up visits and investigations refuse to sign the informed consent form; 11.Other conditions that the researcher considers inappropriate for enrolment.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Pathohistological changes in the gastric mucosa; | — |
Secondary
| Measure | Time frame |
|---|---|
| Gastrointestinal symptom level assessment scale score, blood inflammatory factors (C-reactive protein (CRP), interleukin-1ß (IL-1ß), tumor necrosis factor-a (TNF-a)), pepsinogen, gastrin, riboflavin; | — |
Countries
China
Contacts
Public ContactYu Hong
The Seventh Affiliated Hospital Sun Yat-sen University
Outcome results
None listed